References
- Chou R, Gordon DB, de Leon-Casasola OA, et al. Management of postoperative pain: a clinical practice guideline from the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists' Committee on Regional Anesthesia, Executive Committee, and Administrative Council. J Pain. 2016;17(2):131–157.
- Wang X, Narayan SW, Penm J, et al. Efficacy and safety of tapentadol immediate release for acute pain: a systematic review and meta-analysis. Clin J Pain. 2020;36(5):399–409.
- Parsons N, Griffin XL, Achten J, et al. Modelling and estimation of health-related quality of life after hip fracture: a re-analysis of data from a prospective cohort study. Bone Joint Res. 2018;7(1):1–5.
- Tzschentke TM, Christoph T, Kogel B, et al. (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel mu-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties [research support, Non-U.S. Gov't]. J Pharmacol Exp Ther. 2007;323(1):265–276.
- The Pharmaceutical Benefit Scheme. Tapentadol 2021. [cited 2021 May 26]. Available from: https://www.pbs.gov.au/pbs/search?term=tapentadol
- Husereau D, Drummond M, Petrou S, et al. Consolidated health economic evaluation reporting standards (CHEERS) statement. Value Health. 2013;16(2):e1–e5.
- Faculty of Pain Medicine ANZCA. Recommendations regarding the use of Opioid Analgesics in patients with chronic Non-Cancer Pain, Opioid Dose Equivalence 2015. [cited 2019 Nov 06]. Available from: http://fpm.anzca.edu.au/documents/opioid-dose-equivalence.pdf
- Moayyedi P, Armstrong D, Hunt RH, et al. The gain in quality-adjusted life months by switching to esomeprazole in those with continued reflux symptoms in primary care: EncomPASS–a cluster-randomized trial. Am J Gastroenterol. 2010;105(11):2341–2346.
- Greiner W, Lehmann K, Earnshaw S, et al. Economic evaluation of durogesic in moderate to severe, nonmalignant, chronic pain in Germany. Eur J Health Econ. 2006;7(4):290–296.
- NSW public health system awards and determinations. [cited 2021 April 4]. Available at: https://www.health.nsw.gov.au/careers/conditions/Pages/awards.aspx
- Australian Department of Health. Medicare Benefits Schedule [cited 2021 April 4]. Available from: http://www9.health.gov.au/mbs/search.cfm?q=58903&sopt=I.
- National Hospital Cost Data Collection Report: Public Sector, Round 23 Financial Year 2018-19. Independent Hospital Pricing Authority 2021. [Accessed 2021 April 4]. Available at: https://www.ihpa.gov.au/sites/default/files/publications/round_23_2018-19_nhcdc_report_public_sector.pdf
- Reserve Bank of Australia. Inflation Calculator [cited 2021 April 4]. Available from: https://www.rba.gov.au/calculator/annualDecimal.html
- Australian Government Department of Health. Pharmaceutical Benefits Scheme. AMWG Interim Report to Government – Attachment A [cited 2021 May 18]. Available from: https://www.pbs.gov.au/info/general/working-groups/amwg/amwg-interim-report-attachment-a
- Wang X, Narayan SW, Penm J, et al. Gastrointestinal adverse events in hospitalized patients following orthopedic surgery: tapentadol immediate release versus oxycodone immediate release. Pain Physician. 2021;24(3):E309–E315.
- Apfel CC, Korttila K, Abdalla M, et al. A factorial trial of six interventions for the prevention of postoperative nausea and vomiting. N Engl J Med. 2004;350(24):2441–2451.
- Oderda GM, Evans RS, Lloyd J, et al. Cost of opioid-related adverse drug events in surgical patients. J Pain Symptom Manage. 2003;25(3):276–283.
- StataCorp. Stata statistical software: release 16. College Station (TX): StataCorp LLC; 2019.
- TreeAge Pro 2021, R1. Williamstown, MA. Available from: http://www.treeage.com
- Kwong WJ, Ozer-Stillman I, Miller JD, et al. Cost-effectiveness analysis of tapentadol immediate release for the treatment of acute pain. Clin Ther. 2010;32(10):1768–1781.